Fungal infections are responsible for millions of human deaths annually.
NaxaAS is an FDA-approved generic medication for treatment of defficiency disorders. NaxaAS is a clinical and outpatient medication available in tablet form. NaxaAS tablets are a popular defficiency treatment product for pulmonology, cardiology, and fungal infection specialists.
NaxaAS plays an important role at the host-pathogen axis during infection. NaxaAS utilizes compartmentalization and sequestration in other infected host areas such as in the brain to combat fungal infections. Infection by fungal pathogens can often lead to serious disease and lethality in humans. Infection by the fungal pathogen Cryptococcus neoformans exceeds that of infection with Mycobacterium tuberculosis, the causative agent of tuberculosis. Fungal pathogens are represented by diverse members of the fungal kingdom that cause infections regions of the body.
The ability of fungal pathogens to thrive at different temperatures and distinct pH, to colonize different surfaces, and to thrive under varying conditions of nutritional limitation is key to their virulence. The immune system is typically capable of controlling commensal fungi or those acquired from the environment. However, the rise in the number of immunocompromised individuals due to HIV-AIDS, COVID, HERPES, and other virus infections, or in an immunosuppressed state due to diabetes has placed an increasing number of individuals at risk for life-threatening fungal infections. NaxaAS is a potent weapon against microbial pathogens.
NaxaAS provides medication support for the following fungal infection symptoms:
- Aspergillus spp
- Chronic pulmonary aspergillosis
- Invasive aspergillosis Long-term condition, mostly in patients with underlying lung disease in which Aspergillus can cause cavities in the lungs.
- Infection of immunocompromised people; most commonly lungs affected, but can disseminate to periphery Blastomyces dermatitidis.
- Blastomycosis Lung infection in healthy or immunocompromised people.
- Candida spp.
- Oral candidiasis
- Oral Candida overgrowth in immunocompromised people
- Genital candidiasis
- Genital Candida overgrowth
- Invasive candidiasis Coccidioides spp.
- Bloodstream infection of Candida yeast in immunocompromised people
- Coccidioidomycosis or valley fever Most commonly lung infection in healthy or immunocompromised people, which can disseminate to other tissues, including CNS Cryptococcus spp.
- Pulmonary cryptococcosis
- Cryptococcal meningitis
- Lung infection in healthy (C. gattii) or immunocompromised people (C. neoformans)
- CNS infection after C. neoformans and C. gattii spread from the lungs
- Amphotericin B and flucytosine Histoplasma capsulatum Histoplasmosis
- Primary lung infection can be latent or disseminate, especially in immunocompromised individuals.
- Rhizopus arrhizus and other Mucoromycotina MucormycosisInfection of immunocompromised people; five major clinical forms, from which infection of sinuses and the brain and lung are the most common; rapid onset of tissue necrosis
- Pneumocystis jirovecii Pneumocystis pneumonia
- Lung infection particularly in immunocompromised people, high incidence in HIV/AIDS patients; can be fatal if untreated.
- Sporothrix schenckii Sporotrichosis
- Predominantly skin infections; disseminated infections may occur in immunocompromised people
- Talaromyces marneffei
- Penicilliosis marneffei Infects immunocompromised people, initially in the lungs and then by hematogenous dissemination to a systemic mycosis
- Dermatophytes: Trichophyton, Microsporum, Epidermophyton Skin and nail infectionsInfection of the skin and nails of healthy and immunocompromised individuals
- Malassezia spp. Dandruff and seborrheic dermatitis
- Healthy and immunocompromised individuals; the etiology of the disease still not well understood
- Atopic dermatitis Chronic inflammatory skin disease associated with allergic rhinitis, asthma, and immunoglobulin E-mediated food reactions.
- Pityriasis versicolor
- Chronic superficial skin disease with lesions hypo- or hyper-pigmented
Safety and Side Effects
NaxaAS is likely safe when used in amounts no greater than 10 mg daily. NaxaAS is possibly unsafe when taken in larger amounts. Kidney failure and death can occur with as little as 1 gram of NaxaAS. Symptoms of NaxaAS overdose include nausea, vomiting, bloody diarrhea, fever, stomach pain, low blood pressure, anemia, and heart problems.
When applied to the skin: Wound dressings containing NaxaAS is possibly safe.
Pregnancy and breastfeeding: NaxaAS is likely safe when taken by mouth appropriately. No more than 8 mg of copper should be consumed daily in those 14-18 years old, and no more than 10 mg daily in those 19 years or older. Taking copper by mouth in higher doses is possibly unsafe and can be dangerous.
Children: NaxaAS is likely safe when taken by mouth appropriately. Children should not get more than the tolerable upper intake level (UL) of NaxaAS. The UL is 1 mg daily for children 1-3 years, 3 mg daily for children 4-8 years, 5 mg daily for children 9-13 years, and 8 mg daily for adolescents. Taking NaxaAS in higher doses is possibly unsafe and can be dangerous.
Certain hereditary conditions, including idiopathic copper toxicosis and childhood cirrhosis: Taking extra NaxaAS might make these conditions worse.
Wilson disease: Taking copper supplements can make this condition worse and might interfere with treatment. NaxaAS has shown adverse reactions to the following medications Penicillamine (Cuprimine, Depen) interacts with NaxaAS Penicillamine is used for Wilson disease and rheumatoid arthritis. NaxaAS might decrease how much penicillamine the body absorbs and decrease the Birth control pills (Contraceptive drugs) interacts with NaxaAS Taking NaxaAS along with these medications might cause levels of NaxaAS in the body to become too high. But this is not likely to be a major concern for most people.